New gene therapy improves the life of 18-year-old with Sickle Cell Disease which affects 5,000 New Jersey residents living ...

Sanofi SNY announced that the FDA has granted orphan drug designation to its investigational BTK inhibitor, rilzabrutinib, ...

An annual review of clinical trials for Alzheimer's disease highlights a growing number of active trials—and drugs—in the ...

An algorithm is helping to reduce the number of unnecessary hospital admissions for children with sickle cell.

Sanofi announced today that the U.S. FDA has granted orphan drug designation to rilzabrutinib for the treatment of sickle ...

Rilzabrutinib granted orphan drug designation in the US for sickle cell disease <li /> Fourth orphan drug designation for rilzabrutinib ...

Intellia has leveraged its expertise in Crispr/Cas9 gene editing to advance a pipeline of in vivo and ex vivo therapies for diseases with high unmet medical needs. We believe Intellia's proprietary ...

Beam Therapeutics faces slow pipeline progress and high R&D costs despite a $500M cash boost. Learn why patience is key for ...

Q1 2025 Earnings Call Transcript May 27, 2025 BioLineRx Ltd. beats earnings expectations. Reported EPS is $1.39, expectations were $-0.84. Operator: Ladies and gentlemen, thank you for standing by.

Discover BioLineRx's Q1 2025 highlights, including APHEXDA growth, cost reductions, pipeline expansion, and updates on oncology trials.

Pfizer (NYSE: PFE) is a great example, with its shares down around 57% below the previous high. When a stock plunges as much ...